ID

15837

Descripción

Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00136487

Link

https://clinicaltrials.gov/show/NCT00136487

Palabras clave

Versiones (1)
  1. 15/6/16 15/6/16 -
Subido en

15 de junio de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00136487

Inglés

Eligibility Prostate Cancer NCT00136487

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of prostate cancer
Descripción

prostate cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0600139
progression following prostatectomy or radiation to the prostate, defined as 3 psa rises, with each psa determination at least 4 weeks apart
Descripción

disease progression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C0138741
UMLS CUI [3,1]
C0033573
UMLS CUI [3,2]
C1522449
psa greater than or equal to 1.0 for men who had a prostatectomy
Descripción

psa

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0138741
psa greater than or equal to 3.0 for men who were treated with primary radiation therapy (external beam and/or brachytherapy)
Descripción

psa radiation therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C1522449
psa doubling time between 6 and 24 months
Descripción

psa doubling time

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C1521828
UMLS CUI [1,3]
C1518823
participants must be either fully active and asymptomatic or symptomatic but fully ambulatory
Descripción

fully active and asymptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0205177
UMLS CUI [2]
C0231221
adequate bone marrow function, kidney function and liver function as evidenced by laboratory results
Descripción

bone marrow function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005953
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
evidence of metastatic disease
Descripción

metastatic disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027627
prior hormonal therapy for recurrent prostate cancer
Descripción

hormonal therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C0278838
prior chemotherapy for recurrent or metastatic prostate cancer
Descripción

chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
radiation therapy within 6 months
Descripción

radiation therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
patients allergic to non-steroidal anti-inflammatory drugs (nsaids), salicylates or sulfonamide-type medications who experience asthma or urticaria (hives) after taking aspirin or other nsaids
Descripción

allergy to nsaids

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0003211
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0036077
patients taking a dose of aspirin greater than or equal to 325 mg a day within 4 weeks of study entry
Descripción

aspirin

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0178602
patients taking selective cox-2 inhibitors or any nsaids other than aspirin within 8 weeks of study entry
Descripción

selective cox-2 inhibitors

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1257954
patients taking fluconazole, lithium or warfarin
Descripción

fluconazole lithium or warfarin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0016277
UMLS CUI [2]
C0023870
UMLS CUI [3]
C0043031
history of gastrointestinal or abdominal ulceration or any history of significant gastrointestinal bleeding in the past 12 months
Descripción

ulceration or bleeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0237938
UMLS CUI [2]
C0017181
any history of myocardial infarction in the past 12 months
Descripción

myocardial infarction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027051
any uncontrolled, serious medical or psychiatric illness
Descripción

serious medical or psychiatric illness

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT00136487

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
prostate cancer
Item
diagnosis of prostate cancer
boolean
C0600139 (UMLS CUI [1])
disease progression
Item
progression following prostatectomy or radiation to the prostate, defined as 3 psa rises, with each psa determination at least 4 weeks apart
boolean
C0242656 (UMLS CUI [1])
C0138741 (UMLS CUI [2])
C0033573 (UMLS CUI [3,1])
C1522449 (UMLS CUI [3,2])
psa
Item
psa greater than or equal to 1.0 for men who had a prostatectomy
boolean
C0138741 (UMLS CUI [1])
psa radiation therapy
Item
psa greater than or equal to 3.0 for men who were treated with primary radiation therapy (external beam and/or brachytherapy)
boolean
C0138741 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
psa doubling time
Item
psa doubling time between 6 and 24 months
boolean
C0138741 (UMLS CUI [1,1])
C1521828 (UMLS CUI [1,2])
C1518823 (UMLS CUI [1,3])
fully active and asymptomatic
Item
participants must be either fully active and asymptomatic or symptomatic but fully ambulatory
boolean
C0205177 (UMLS CUI [1])
C0231221 (UMLS CUI [2])
bone marrow function
Item
adequate bone marrow function, kidney function and liver function as evidenced by laboratory results
boolean
C0005953 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
metastatic disease
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1])
hormonal therapy
Item
prior hormonal therapy for recurrent prostate cancer
boolean
C0279025 (UMLS CUI [1,1])
C0278838 (UMLS CUI [1,2])
chemotherapy
Item
prior chemotherapy for recurrent or metastatic prostate cancer
boolean
C0392920 (UMLS CUI [1])
radiation therapy
Item
radiation therapy within 6 months
boolean
C1522449 (UMLS CUI [1])
allergy to nsaids
Item
patients allergic to non-steroidal anti-inflammatory drugs (nsaids), salicylates or sulfonamide-type medications who experience asthma or urticaria (hives) after taking aspirin or other nsaids
boolean
C0020517 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0036077 (UMLS CUI [2,2])
aspirin
Item
patients taking a dose of aspirin greater than or equal to 325 mg a day within 4 weeks of study entry
boolean
C0004057 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
selective cox-2 inhibitors
Item
patients taking selective cox-2 inhibitors or any nsaids other than aspirin within 8 weeks of study entry
boolean
C1257954 (UMLS CUI [1])
fluconazole lithium or warfarin
Item
patients taking fluconazole, lithium or warfarin
boolean
C0016277 (UMLS CUI [1])
C0023870 (UMLS CUI [2])
C0043031 (UMLS CUI [3])
ulceration or bleeding
Item
history of gastrointestinal or abdominal ulceration or any history of significant gastrointestinal bleeding in the past 12 months
boolean
C0237938 (UMLS CUI [1])
C0017181 (UMLS CUI [2])
myocardial infarction
Item
any history of myocardial infarction in the past 12 months
boolean
C0027051 (UMLS CUI [1])
serious medical or psychiatric illness
Item
any uncontrolled, serious medical or psychiatric illness
boolean
C0009488 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial